segigratinib (3D185)
/ HaiHe Biopharma, 3DMed
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
May 30, 2025
A Monotherapy in Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=42 | Active, not recruiting | Sponsor: 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Dec 2024 ➔ Dec 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025
Monotherapy • Trial completion date • Trial primary completion date • Solid Tumor
May 20, 2025
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
(clinicaltrials.gov)
- P2 | N=50 | Not yet recruiting | Sponsor: 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Jun 2026 ➔ Jun 2028 | Trial primary completion date: Dec 2025 ➔ Dec 2027
Monotherapy • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor • FGFR
August 23, 2024
A Monotherapy in Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=42 | Active, not recruiting | Sponsor: 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Jun 2024 ➔ Dec 2024 | Trial primary completion date: Jun 2024 ➔ Dec 2024
Metastases • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
January 31, 2024
A Monotherapy in Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=42 | Active, not recruiting | Sponsor: 3D Medicines (Beijing) Co., Ltd. | Recruiting ➔ Active, not recruiting
Enrollment closed • Oncology • Solid Tumor
October 13, 2023
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
(clinicaltrials.gov)
- P2 | N=50 | Not yet recruiting | Sponsor: 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Jun 2024 ➔ Jun 2026 | Trial primary completion date: Dec 2023 ➔ Dec 2025
Metastases • Monotherapy • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • FGFR
April 11, 2023
A Monotherapy in Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1 | N=42 | Recruiting | Sponsor: 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Dec 2023 ➔ Jun 2024 | Trial primary completion date: Jun 2023 ➔ Dec 2023
Metastases • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
April 11, 2023
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
(clinicaltrials.gov)
- P2 | N=50 | Not yet recruiting | Sponsor: 3D Medicines (Beijing) Co., Ltd. | Trial completion date: Dec 2026 ➔ Jun 2024 | Trial primary completion date: Dec 2026 ➔ Dec 2023
Metastases • Monotherapy • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • FGFR
September 10, 2021
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma
(clinicaltrials.gov)
- P2; N=50; Not yet recruiting; Sponsor: 3D Medicines (Beijing) Co., Ltd.
Clinical • Monotherapy • New P2 trial • Biliary Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor • FGFR
August 31, 2021
A Monotherapy in Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1; N=42; Recruiting; Sponsor: 3D Medicines (Beijing) Co., Ltd.; Trial completion date: Dec 2022 ➔ Dec 2023; Trial primary completion date: Jun 2022 ➔ Jun 2023
Clinical • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
March 24, 2021
A Monotherapy in Subjects With Advanced Solid Tumors
(clinicaltrials.gov)
- P1; N=42; Recruiting; Sponsor: 3D Medicines (Sichuan) Co., Ltd.; Trial completion date: Sep 2020 ➔ Dec 2022; Trial primary completion date: Apr 2020 ➔ Jun 2022
Clinical • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor
1 to 10
Of
10
Go to page
1